Christoph Funk

3.2k total citations
55 papers, 2.1k citations indexed

About

Christoph Funk is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, Christoph Funk has authored 55 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 21 papers in Pharmacology and 12 papers in Molecular Biology. Recurrent topics in Christoph Funk's work include Drug Transport and Resistance Mechanisms (24 papers), Pharmacogenetics and Drug Metabolism (18 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Christoph Funk is often cited by papers focused on Drug Transport and Resistance Mechanisms (24 papers), Pharmacogenetics and Drug Metabolism (18 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Christoph Funk collaborates with scholars based in Switzerland, Germany and United States. Christoph Funk's co-authors include Renée Portmann, Agnès Poirier, Johannes Noé, Thierry Lavé, Michael Pantze, Adrian Roth, Franz Schuler, Lutz Breuer, Archana Raghavan Sathyan and Peter Winker and has published in prestigious journals such as PLoS ONE, Scientific Reports and Research Policy.

In The Last Decade

Christoph Funk

55 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christoph Funk Switzerland 26 1.0k 757 494 434 204 55 2.1k
Hugh A. Barton United States 34 761 0.7× 888 1.2× 449 0.9× 515 1.2× 133 0.7× 102 3.5k
Jinghai J. Xu United States 14 416 0.4× 715 0.9× 191 0.4× 548 1.3× 127 0.6× 23 1.8k
Robert Elsby United Kingdom 20 729 0.7× 551 0.7× 363 0.7× 367 0.8× 109 0.5× 25 1.6k
Elaine M. Leslie Canada 28 2.5k 2.4× 451 0.6× 933 1.9× 1.1k 2.5× 231 1.1× 50 3.9k
Partha Krishnamurthy United States 27 923 0.9× 233 0.3× 291 0.6× 1.2k 2.7× 474 2.3× 45 2.9k
J. Greg Slatter United States 21 666 0.6× 540 0.7× 166 0.3× 762 1.8× 87 0.4× 50 1.9k
Éric Lévesque Canada 32 721 0.7× 1.3k 1.7× 478 1.0× 1.4k 3.3× 98 0.5× 101 3.1k
Jacqueline Ramı́rez United States 31 2.1k 2.0× 926 1.2× 659 1.3× 2.1k 4.9× 157 0.8× 77 3.8k
Georges de Sousa France 31 481 0.5× 656 0.9× 109 0.2× 630 1.5× 164 0.8× 76 2.4k
David Carlile United Kingdom 24 1.1k 1.1× 844 1.1× 126 0.3× 517 1.2× 85 0.4× 55 2.3k

Countries citing papers authored by Christoph Funk

Since Specialization
Citations

This map shows the geographic impact of Christoph Funk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Funk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Funk more than expected).

Fields of papers citing papers by Christoph Funk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Funk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Funk. The network helps show where Christoph Funk may publish in the future.

Co-authorship network of co-authors of Christoph Funk

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Funk. A scholar is included among the top collaborators of Christoph Funk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Funk. Christoph Funk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Funk, Christoph, et al.. (2024). Reading between the lines: The intersection of research attention and sustainable development goals. Sustainable Development. 32(5). 4545–4566. 1 indexed citations
2.
Kemp, Luke, et al.. (2022). Focus of the IPCC Assessment Reports Has Shifted to Lower Temperatures. Earth s Future. 10(5). 14 indexed citations
3.
McAleer, Christopher W., Christopher J. Long, Daniel Elbrecht, et al.. (2019). Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics. Science Translational Medicine. 11(497). 141 indexed citations
4.
Schadt, Simone, Bojan Bister, Swapan K. Chowdhury, et al.. (2018). A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the “Metabolites in Safety Testing” Regulatory Guidance. Drug Metabolism and Disposition. 46(6). 865–878. 78 indexed citations
5.
Kratochwil, Nicole A., Christophe Meille, Stephen Fowler, et al.. (2017). Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling. The AAPS Journal. 19(2). 534–550. 88 indexed citations
6.
7.
8.
Funk, Christoph & Adrian Roth. (2016). Current limitations and future opportunities for prediction of DILI from in vitro. Archives of Toxicology. 91(1). 131–142. 41 indexed citations
9.
Brink, Andreas, Axel Pähler, Christoph Funk, Franz Schuler, & Simone Schadt. (2016). Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design. Drug Discovery Today. 22(5). 751–756. 30 indexed citations
10.
Jones, Russell G., Michael Keller, Na Qiu, et al.. (2015). Shedding light on minipig drug metabolism – elevated amide hydrolysisin vitro. Xenobiotica. 46(6). 483–494. 4 indexed citations
11.
Brennan, Barbara J., Agnès Poirier, Peter N. Morcos, et al.. (2014). Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir. Clinical Pharmacokinetics. 54(5). 537–549. 12 indexed citations
12.
Poirier, Agnès, Renée Portmann, Isabelle Walter, et al.. (2014). Calibration of In Vitro Multidrug Resistance Protein 1 Substrate and Inhibition Assays as a Basis to Support the Prediction of Clinically Relevant Interactions In Vivo. Drug Metabolism and Disposition. 42(9). 1411–1422. 37 indexed citations
13.
14.
Caruso, Antonello, Rubén Alvarez‐Sánchez, Alexander Hillebrecht, et al.. (2013). PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation. Biochemical Pharmacology. 85(11). 1684–1699. 24 indexed citations
15.
Kuhlmann, Olaf, et al.. (2010). Pharmacokinetics and metabolism of the dipeptidyl peptidase IV inhibitor carmegliptin in rats, dogs, and monkeys. Xenobiotica. 40(12). 840–852. 6 indexed citations
16.
Poirier, Agnès, Thierry Lavé, Renée Portmann, et al.. (2008). Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model. Drug Metabolism and Disposition. 36(12). 2434–2444. 80 indexed citations
17.
18.
Letizia, C.S., et al.. (2000). Food and chemical toxicology.. PubMed. 38 Suppl 3. S1–236. 13 indexed citations
19.
Gasser, Robin B., et al.. (1999). Use of Transgenic Cell Lines in Mechanistic Studies of Drug Metabolism. Toxicology in Vitro. 13(4-5). 625–632. 5 indexed citations
20.
Zhi, Jianguo, Angela T. Melia, Christoph Funk, et al.. (1996). Metabolic Profiles of Minimally Absorbed Orlistat in Obese/Overweight Volunteers. The Journal of Clinical Pharmacology. 36(11). 1006–1011. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hugh A. Barton Breakdown of academic impact, for papers by Jinghai J. Xu Breakdown of academic impact, for papers by Robert Elsby Breakdown of academic impact, for papers by Elaine M. Leslie Breakdown of academic impact, for papers by Partha Krishnamurthy Breakdown of academic impact, for papers by J. Greg Slatter Breakdown of academic impact, for papers by Éric Lévesque Breakdown of academic impact, for papers by Jacqueline Ramı́rez Breakdown of academic impact, for papers by Georges de Sousa Breakdown of academic impact, for papers by David Carlile
Rankless by CCL
2026